Abstract
Transforming growth factor β (TGFβ) is important in maintaining self-tolerance and inhibits T cell reactivity. We show that CD8+ T cells that lack the tyrosine phosphatase Ptpn22, a major predisposing gene for autoimmune disease, are resistant to the suppressive effects of TGFβ. Resistance to TGFβ suppression, while disadvantageous in autoimmunity, helps Ptpn22 -/- T cells to be intrinsically superior at clearing established tumors that secrete TGFβ. Mechanistically, loss of Ptpn22 increases the capacity of T cells to produce IL-2, which overcomes TGFβ-mediated suppression. These data suggest that a viable strategy to improve anti-tumor adoptive cell therapy may be to engineer tumor-restricted T cells with mutations identified as risk factors for autoimmunity.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Autoimmunity / immunology
-
CD8-Positive T-Lymphocytes / drug effects
-
CD8-Positive T-Lymphocytes / immunology*
-
CD8-Positive T-Lymphocytes / transplantation
-
Female
-
Homeodomain Proteins / genetics
-
Immunotherapy, Adoptive / methods*
-
Interleukin-2 / metabolism
-
Male
-
Mice, Mutant Strains
-
Mice, Transgenic
-
Ovalbumin / pharmacology
-
Ovarian Neoplasms / pathology
-
Ovarian Neoplasms / therapy
-
Peptide Fragments / pharmacology
-
Protein Tyrosine Phosphatase, Non-Receptor Type 22 / genetics*
-
Protein Tyrosine Phosphatase, Non-Receptor Type 22 / metabolism
-
Receptors, Transforming Growth Factor beta / metabolism
-
Transforming Growth Factor beta / metabolism
-
Transforming Growth Factor beta / pharmacology*
Substances
-
Homeodomain Proteins
-
Interleukin-2
-
OVA-8
-
Peptide Fragments
-
Receptors, Transforming Growth Factor beta
-
Transforming Growth Factor beta
-
RAG-1 protein
-
Ovalbumin
-
Protein Tyrosine Phosphatase, Non-Receptor Type 22
-
Ptpn22 protein, mouse